803
Participants
Start Date
September 30, 2007
Primary Completion Date
July 31, 2009
Study Completion Date
January 31, 2010
peginesatide
Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
Epoetin Alfa
Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
Research Facility, New York
Research Facility, The Bronx
Research Facility, The Bronx
Research Facility, Yonkers
Research Facility, Brooklyn
Research Facility, Williamsville
Research Facility, Pittsburgh
Research Facility, Allentown
Research Facility, Philadelphia
Research Facility, Philadelphia
Research Facility, Bethesda
Research Facility, Rockville
Research Facility, Fairfax
Research Facility, Alexandria
Research Facility, Mechanicsville
Research Facility, Chesapeake
Research Facilities (2), Norfolk
Research Facility, Morgantown
Research Facility, Raleigh
Research Facility, Durham
Research Facility, Sumter
Research Facilities (2), Greenville
Research Facility, Decatur
Research Facility, Marietta
Research Facility, Augusta
Research Facility, Augusta
Research Facility, Orlando
Research Facility, Orlando
Research Facility, Pembroke Pines
Research Facility, Ocala
Research Facility, Hudson
Research Facility, Nashville
Research Facility, Knoxville
Research Facility, Dyersburg
Research Facility, Tupelo
Research Facility, Columbus
Research Facility, Lexington
Research Facility, Columbus
Research Facility, Canton
Research Facility, Cincinnati
Research Facility, Evansville
Research Facility, Dearborn
Research Facility, Kalamazoo
Research Facility, Oshkosh
Research Facility, Appleton
Research Facility, Gurnee
Research Facility, Chicago
Research Facility, Evergreen Park
Research Facility, Peoria
Research Facility, St Louis
Research Facility, Wichita
Research Facility, New Orleans
Research Facility, Lafayette
Research Facility, Baton Rouge
Research Facility, Shreveport
Research Facility, Paragould
Research Facility, Grand Prairie
Research Facility, Tyler
Research Facility, Arlington
Research Facility, Fort Worth
Research Facility, Fort Worth
Research Facility, Fort Worth
Research Facilities (2), Houston
Research Facility, Houston
Research Facility, San Antonio
Research Facility, San Antonio
Research Facility, McAllen
Research Facility, Denver
Research Facility, Boise
Research Facility, Las Vegas
Research Facility, Los Angeles
Research Facility, Los Angeles
Research Facility, Los Angeles
Research Facility, Lynwood
Research Facility, Whittier
Research Facility, Los Alamitos
Research Facility, Paramount
Research Facility, Granada Hills
Research Facility, Monterey Park
Research Facility, San Dimas
Research Facilities (2), San Diego
Research Facility, Mountain View
Research Facility, Fairfield
Research Facility, Honolulu
Research Facility, Roseburg
Research Facility, Middlebury
Research Facility, Fall River
Research Facility, Worcester
Research Facility, Eatontown